Reckitt Benckiser Group plc successfully completed its acquisition of Adams Respiratory Therapeutics Inc. through a cash tender offer followed by a short- form merger of its indirect wholly owned subsidiary, Twickenham Inc., with and into Adams.
Reckitt Benckiser Group plc and Adams Respiratory Therapeutics have entered into a definitive agreement under which Reckitt Benckiser will tender for the acquisition of Adams for $60 per share in cash ($2.3 billion).
At a recent shareholders meeting, P&G President and Chief Executive A. G. Lafley said, "We are now focused on delivering a full decade of industry-leading top and bottom line growth.
